( MENAFN - GlobeNewsWire - Nasdaq) WALTHAM, Mass., May 19, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced it now plans to report new efficacy and safety data from its Phase 1/2 ACHIEVE and DELIVER clinical trials on May 20, 2024, and to host a virtual event at 8:00 a.

m. ET. This represents an update to Dyne's prior guidance for the second half of 2024.

The company intends to issue a press release prior to the start of the event. Phase 1/2 ACHIEVE Trial of DYNE-101 in DM1 Phase 1/2 DELIVER Trial of DYNE-251 in DMD Virtual Investor Event The live event webcast will be available on the Events & Presentations page of the Investors & Media section of Dyne's website and a replay will be accessible for 90 days following the presentation. An accompanying slide presentation will also be available.

To register for the live webcast and replay, please visit . About Dyne Therapeutics Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCETM platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue.

Dyne has a broad pipeline for serious muscle diseases, including clinical programs fo.